Pharma-Bio Serv (PBSV) Net Cash Flow (2010 - 2026)

Pharma-Bio Serv (PBSV) has reported Net Cash Flow for 17 consecutive years, with -$4.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow rose 24.59% year-over-year to -$4.0 million; the trailing twelve-month figure through Apr 2026 stood at -$321755.0 (up 77.64% YoY), and the FY2025 full-year result was -$3.4 million, up 6.24% from the prior year.
• Net Cash Flow slipped to -$4.0 million in Q2 2026 per PBSV's latest filing, from $2.4 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $7.6 million in Q4 2023 and bottomed at -$7.3 million in Q1 2023.
• Historically, Net Cash Flow has averaged -$873916.7 across 5 years, with a median of -$170313.0 in 2022.
• The widest YoY moves for Net Cash Flow: up 3008.91% in 2023, down 577.36% in 2023.
• Over 5 years, Net Cash Flow stood at $245575.0 in 2022, then soared by 3008.91% to $7.6 million in 2023, then slumped by 96.73% to $249957.0 in 2024, then tumbled by 334.52% to -$586201.0 in 2025, then slumped by 577.37% to -$4.0 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$4.0 million, $2.4 million, and -$586201.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.